<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03992378</url>
  </required_header>
  <id_info>
    <org_study_id>9227</org_study_id>
    <nct_id>NCT03992378</nct_id>
  </id_info>
  <brief_title>Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis</brief_title>
  <acronym>NERINA-SEPSIS</acronym>
  <official_title>Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oklahoma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oklahoma City VA Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oklahoma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sepsis is life-threatening organ dysfunction caused by a dysregulated host response to&#xD;
      infection. It is the most expensive healthcare condition to treat in United States and has a&#xD;
      mortality rate of nearly 30%. It is widely known that exaggerated inflammation and imbalance&#xD;
      between sympathetic and parasympathetic arms of the autonomic nervous system (ANS) contribute&#xD;
      to progression and adverse outcomes in sepsis. The role of unchecked inflammation and&#xD;
      unregulated ANS as a potential treatment target is an important gap in our knowledge that&#xD;
      should be explored.&#xD;
&#xD;
      Cholinergic anti-inflammatory pathway (CAP) is an intricate network where the ANS senses&#xD;
      inflammation by vagus nerve afferents and tries to regulate it by vagus nerve efferents to&#xD;
      the reticuloendothelial system. The central hypothesis of this pilot clinical trial is that&#xD;
      transcutaneous vagus nerve stimulation (TVNS) at tragus of the external ear can activate the&#xD;
      CAP to suppress inflammation and improve autonomic imbalance as measured by inflammatory&#xD;
      cytokine levels and heart rate variability (HRV) analysis. The investigators plan to&#xD;
      randomize patients with septic shock into active and sham stimulation groups and study the&#xD;
      effects of vagal stimulation on inflammatory cytokines, HRV and a clinical severity score of&#xD;
      sepsis. Both groups will continue to receive the standard of care treatment for sepsis&#xD;
      irrespective of group assignments. The investigators hypothesize that 4 hours of TVNS will&#xD;
      suppress inflammatory markers and improve the balance between sympathetic and parasympathetic&#xD;
      arms of ANS as measured by HRV, resulting in improved Sequential Organ Failure Assessment&#xD;
      Score (SOFA). The preliminary data generated from this pilot study will lay the foundation&#xD;
      for a larger clinical trial.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 2020</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>Double blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Inflammatory Cytokine Tumor Necrosis Factor Alpha</measure>
    <time_frame>Baseline to 4 hours and baseline to 24 hours post stimulation</time_frame>
    <description>Serum inflammatory cytokine</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Heart Rate Variability</measure>
    <time_frame>Baseline to 4 hours post stimulation</time_frame>
    <description>Time domain and frequency domain measures of heart rate variability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Sequential Organ Failure Assessment Score</measure>
    <time_frame>Baseline to 24 hours post stimulation</time_frame>
    <description>Sequential Organ Failure Assessment Score calculation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>Active Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive a single 4-hour session of active transcutaneous vagus nerve stimulation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Patients will receive a single 4-hour session of sham transcutaneous vagus nerve stimulation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Low Level Transcutaneous Vagus Nerve Stimulation</intervention_name>
    <description>Stimulation of the auricular branch of the vagus nerve at tragus of the external ear delivered by Parasym device.</description>
    <arm_group_label>Active Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Low Level Transcutaneous Vagus Nerve Stimulation</intervention_name>
    <description>Stimulation of the ear lobe delivered by Parasym device.</description>
    <arm_group_label>Sham Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Septic shock (meeting severe sepsis and having persistent systolic blood pressure &lt;90mmHg&#xD;
        despite adequate fluid resuscitation).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unilateral or bilateral vagotomy&#xD;
&#xD;
          -  History of myocardial infarction or stroke in the last 1 year&#xD;
&#xD;
          -  Recurrent vasovagal syncope&#xD;
&#xD;
          -  Sick sinus syndrome without pacemaker&#xD;
&#xD;
          -  Bifascicular heart block&#xD;
&#xD;
          -  2nd or 3rd-degree heart block&#xD;
&#xD;
          -  Hypotension due to autonomic dysfunction&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Prisoners and patients with suicidal ideation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Houssein Youness, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oklahoma</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zain Ul Abideen Asad, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oklahoma</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Houssein Youness, MD</last_name>
    <phone>405-271-6173</phone>
    <email>Houssein-Youness@ouhsc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zain Ul Abideen Asad, MD</last_name>
    <phone>405-271-5963</phone>
    <email>Zain-Asad@ouhsc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Sinko, RN</last_name>
      <phone>405-271-6173</phone>
      <email>Lauren-A-Sinko@ouhsc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kassidy Malone, RN</last_name>
      <phone>4052716173</phone>
      <email>Kassidy-Malone@ouhsc.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>June 5, 2019</study_first_submitted>
  <study_first_submitted_qc>June 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2019</study_first_posted>
  <last_update_submitted>October 15, 2020</last_update_submitted>
  <last_update_submitted_qc>October 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sepsis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

